RMD vs WST — Key Metrics
| Metric | RMD (RESMED INC) | WST (WEST PHARMACEUTICAL SERVICES INC) |
|---|---|---|
| Price | 221.1 | 370.76 |
| Market Cap | 31.89 Billion | 26.09 Billion |
| P/E (TTM) | 21.12 | 47.11 |
| P/B (Quarterly) | 4.967 | 8.366 |
| P/S (TTM) | 5.64 | 7.84 |
| Net Profit Margin (TTM) | 26.9 | 17.0 |
| Gross Margin (TTM) | 61.1 | 36.8 |
| ROE (TTM) | 23.9 | 18.5 |
| Revenue Growth YoY (TTM) | None | None |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
RMD · RESMED INC
Underperform
WST · WEST PHARMACEUTICAL SERVICES INC
Greatly Underperform
Recommendation Summary
Stock RMD is projected to underperform the market, stock WST is projected to greatly underperform the market. Upfront Recommendation: RMD.
Financial Metrics
Prices delayed ~15 min
| RMD | Metrics | WST |
|---|---|---|
| $221.10 | Price | $370.76 |
| — | Market Capitalization | — |
| 21.12 | Price to Earnings Ratio | 47.11 |
| 5.64 | Price to Sales | 7.84 |
| 19.34 | Price to FCF Ratio | 59.72 |
| 9.24 | Price to Gross Profit | 21.32 |
| 84.31 | Price to R&D | 350.71 |
| 7.37 | Price to Current Assets | 14.44 |